Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Estrella Immunopharma reported encouraging initial tolerability in the first patient receiving two EB103 infusions in STARLIGHT-1’s dose-expansion phase for relapsed/refractory B-cell non-Hodgkin’s lymphoma. The patient received infusions three weeks apart, with no treatment-related serious adverse events reported duri
For best results when printing this announcement, please click on link below: Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase Patient received two infusions three weeks apart at the recommended Phase II dose; no treatment-related serious adverse events observed th
The patient received two EB103 infusions.